Summary of: Shao C, Li G, Huang L, Pruitt S, Castellanos E, Frampton G, Carson K, Snow T, Singal G, Fabrizio BS, Alexander BM, Jin F, Zhou W. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors. JAMA Netw Open. 2020;3(10):e2025109.
While tumor mutational burden (TMB) is an emerging biomarker that may be associated with response to immune checkpoint inhibitor therapies, the prognostic value associated with TMB in the absence of immunotherapy is uncertain.
This study sought to assess the prevalence of high TMB and its association with overall survival among patients with the same tumor types as the clinical trial cohort but who hadn’t been treated with immunotherapy.